Brokerages expect Merck & Co. (NYSE:MRK) to report $1.04 earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have provided estimates for Merck & Co.’s earnings. The lowest EPS estimate is $1.02 and the highest is $1.06. Merck & Co. posted earnings of $1.01 per share during the same quarter last year, which suggests a positive year-over-year growth rate of 3%. The business is expected to issue its next earnings report on Friday, July 27th.
According to Zacks, analysts expect that Merck & Co. will report full-year earnings of $4.22 per share for the current fiscal year, with EPS estimates ranging from $4.14 to $4.29. For the next fiscal year, analysts expect that the firm will post earnings of $4.50 per share, with EPS estimates ranging from $4.27 to $4.65. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Merck & Co..
Merck & Co. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, May 1st. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.00 by $0.05. The firm had revenue of $10.04 billion for the quarter, compared to analyst estimates of $10.09 billion. Merck & Co. had a return on equity of 30.93% and a net margin of 4.31%. The business’s revenue was up 6.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.88 earnings per share.
A number of equities analysts have weighed in on MRK shares. BMO Capital Markets set a $65.00 price objective on Merck & Co. and gave the stock a “buy” rating in a research note on Thursday, March 8th. DZ Bank raised Merck & Co. from a “hold” rating to a “buy” rating in a research note on Tuesday, February 13th. Bank of America boosted their price objective on Merck & Co. from $68.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, April 17th. Zacks Investment Research raised Merck & Co. from a “hold” rating to a “buy” rating and set a $66.00 price objective on the stock in a research note on Tuesday, April 17th. Finally, Goldman Sachs Group raised Merck & Co. from a “neutral” rating to a “buy” rating and lowered their price objective for the stock from $60.15 to $58.83 in a research note on Monday, April 23rd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have issued a buy rating to the company. Merck & Co. presently has a consensus rating of “Buy” and an average target price of $65.87.
NYSE MRK traded down $0.04 on Friday, reaching $59.09. 6,665,374 shares of the company were exchanged, compared to its average volume of 9,525,584. The firm has a market capitalization of $159.32 billion, a P/E ratio of 14.85, a price-to-earnings-growth ratio of 2.25 and a beta of 0.76. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.10 and a current ratio of 1.42. Merck & Co. has a fifty-two week low of $52.83 and a fifty-two week high of $66.41.
The firm also recently declared a quarterly dividend, which will be paid on Monday, July 9th. Stockholders of record on Friday, June 15th will be paid a $0.48 dividend. This represents a $1.92 annualized dividend and a dividend yield of 3.25%. The ex-dividend date of this dividend is Thursday, June 14th. Merck & Co.’s dividend payout ratio (DPR) is presently 48.24%.
In other news, EVP Julie L. Gerberding sold 9,972 shares of the company’s stock in a transaction on Tuesday, May 15th. The stock was sold at an average price of $59.66, for a total value of $594,929.52. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Weir Mirian M. Graddick sold 24,000 shares of the company’s stock in a transaction on Monday, April 16th. The shares were sold at an average price of $58.00, for a total value of $1,392,000.00. The disclosure for this sale can be found here. Corporate insiders own 0.32% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. Great West Life Assurance Co. Can raised its holdings in shares of Merck & Co. by 0.7% in the 3rd quarter. Great West Life Assurance Co. Can now owns 3,080,692 shares of the company’s stock valued at $197,605,000 after buying an additional 22,341 shares during the period. Eagle Asset Management Inc. raised its holdings in shares of Merck & Co. by 0.3% in the 3rd quarter. Eagle Asset Management Inc. now owns 1,027,746 shares of the company’s stock valued at $66,341,000 after buying an additional 3,241 shares during the period. Jackson Wealth Management LLC raised its holdings in shares of Merck & Co. by 5.2% in the 3rd quarter. Jackson Wealth Management LLC now owns 60,070 shares of the company’s stock valued at $3,872,000 after buying an additional 2,943 shares during the period. FTB Advisors Inc. raised its holdings in shares of Merck & Co. by 6.4% in the 3rd quarter. FTB Advisors Inc. now owns 62,530 shares of the company’s stock valued at $4,013,000 after buying an additional 3,786 shares during the period. Finally, Amundi Pioneer Asset Management Inc. raised its holdings in shares of Merck & Co. by 415.5% in the 3rd quarter. Amundi Pioneer Asset Management Inc. now owns 3,560,465 shares of the company’s stock valued at $227,977,000 after buying an additional 2,869,844 shares during the period. 73.14% of the stock is currently owned by institutional investors and hedge funds.
Merck & Co. Company Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.